TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20349229
Drug: Calcium 1,000
Normalized name: Calcium 1,000mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 1,000 mg for 1 week followed by Vitamin D3 1,000 i.u. daily for 7 weeks
Study: 20349229
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 1,000 i.u. daily for 7 weeks followed by Calcium 1,000 mg for 1 week
Study: 15777441
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose vaginal misoprostol 25 microg every 4 hours (maximum of six doses)
Study: 15777441
Drug: Dinoprostone vaginal
Normalized name: dinoprostone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinoprostone vaginal gel 1‐2 mg 6 hourly (maximum of 3 mg in 24 hours)
Study: 15777441
Drug: Dinoprostone vaginal
Normalized name: dinoprostone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinoprostone vaginal gel
Study: 2691106
Drug: Compound five-Shen
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound five-Shen herbal drink (CFSHD) - Group I
Study: 2691106
Drug: Compound five-Shen
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound five-Shen herbal drink (CFSHD) - Group II
Study: 23670576
Drug: Endostar (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endostar (7.5 mg/m²) plus dacarbazine (250 mg/m²)
Study: 23670576
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus dacarbazine (250 mg/m²)
Study: 21031343
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with fixed dose of 4 mg rosiglitazone plus 500 mg metformin (RSG+MET group, n = 70)
Study: 21031343
Drug: Half-maximum dose
Normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Half-maximum dose of metformin monotherapy (MET group, n = 70)
Study: 8879373
Drug: Chemotherapy (sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (sequential 5‐fluorouracil/leucovorin combined with etoposide or FLv for elderly/poor performance patients)
Study: 2049700
Drug: Insulin use
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin use among diagnosed diabetics
Study: 6362699
Drug: Nitrazepam 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrazepam 5.0 mg
Study: 26443019
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg zinc tablets daily for 12 months
Study: 26443019
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets daily for 12 months
Study: 22152099
Drug: High-density negative
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-density negative ion (HDNI) treatment
Study: 20546266
Drug: Medication possession
Normalized name: ZINC OXIDE 17.5 g in 100 g TOPICAL LIPSTICK [Lipshade SPF 30 Obsessed]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication possession ratio (MPR)
Study: 20546266
Drug: Morisky Medication-taking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morisky Medication-taking Scale
Study: 20546266
Drug: Medication-taking item
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication-taking item of the Summary of Diabetes Self-Care Activities (SDSCA)
Study: 18056491
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (20 digits)
Study: 18056491
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection (15 digits)
Study: 16211735
Drug: Etomidate (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate (0.2 mg kg[-1])
Study: 16211735
Drug: Propofol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2 mg kg[-1])
Study: 11945098
Drug: Remacemide hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Remacemide (DB06458)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remacemide hydrochloride 1200 mg/day
Study: 8773063
Drug: Mefenamic acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefenamic acid 6.5 mg/kg
Study: 8773063
Drug: Ibuprofen 7
Normalized name: hydrocodone-ibuprofen 7.5 mg-200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 7 mg/kg
Study: 1689173
Drug: Terazosin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin (10 mg/day)
Study: 26549134
Drug: Bilateral infraorbital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral infraorbital and infratrochlear nerve blocks with 10 mL of 0.25% levobupivacaine (Group LB)
Study: 21775113
Drug: Prescription omega-3-acid
Normalized name: OMEGA-3 ACID
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription omega-3-acid ethyl esters (POM3)
Study: 18040542
Drug: Clinical holistic
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical holistic medicine (CHM)
Study: 18040542
Drug: Standard psychiatric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard psychiatric treatment (TAU)
Study: 11897585
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of artemisinin daily for 5 days (group A; n = 40)
Study: 11897585
Drug: Artemisinin at
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin at a dose of 100 mg per day for 2 days, increased to 250 mg per day for 2 consecutive days, and 500 mg on the fifth day (group B; n = 37)
Study: 11897585
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (500 mg daily for 5 days)
Study: 11897585
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (escalating doses of artemisinin)
Study: 10631689
Drug: High-dose (dose-intensive)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (dose-intensive) therapy for breast cancer
Study: 1702552
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of Heparin (Kakkar protocol)
Study: 31534374
Drug: Polyphenol compound
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyphenol compound supplementation (Vertigoval) for 60 days
Study: 28675566
Drug: Glutamine-fiber-oligosaccharide treatment
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine-fiber-oligosaccharide treatment group (n=11)
Study: 28675566
Drug: Glutamine F
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine F treatment group (n=11)
Study: 25851721
Drug: Comprehensive medical
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive medical education program (1h/day for 5 days) and specific drug therapy
Study: 25851721
Drug: Only drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only drug therapy
Study: 23453362
Drug: Initial serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial serum magnesium concentration >1.6 mg/dL
Study: 21084184
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy (CT) with cisplatin (80 mg/m(2)) and infusional 5 fluorouracil (1000 mg/m(2)/d) on days 1 and 21
Study: 21084184
Drug: Preoperative chemoradiation
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemoradiation therapy (CRT) with cisplatin (80 mg/m(2)), infusional 5 fluorouracil (800 mg/m(2)/d) starting on day 21, and radiation therapy (35 Gy in 15 fractions over 3 weeks)
Study: 19833052
Drug: Prednisolone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (50 mg per day)
Study: 19833052
Drug: Aciclovir (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aciclovir (2000 mg per day)
Study: 15371775
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion of 0.25% bupivacaine
Study: 15371775
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose caudal injection of 0.25% bupivacaine
Study: 7732541
Drug: Sodium fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium fluoride tablets administered since age 2
Study: 3133708
Drug: Trazodone (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone (150 mg daily)
Study: 3133708
Drug: Mianserin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin (30 mg for 7 days, then 60 mg daily)
Study: 3133708
Drug: Dothiepin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dothiepin (75 mg for 1 week, then 150 mg daily)
Study: 3133708
Drug: Amitriptyline (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (75 mg for 1 week, then 100 mg daily)
Study: 29903422
Drug: Daily bladder
Normalized name: Pumpkin Seed Extract/Soy Germ 300 MG Oral Capsule [DAILY BLADDER COMFORT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily bladder irrigation with 450 cc sterile normal saline, in 3 150‐mL doses, for 3 consecutive days
Study: 29903422
Drug: Daily bladder
Normalized name: Pumpkin Seed Extract/Soy Germ 300 MG Oral Capsule [DAILY BLADDER COMFORT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily bladder irrigation with normal saline
Study: 21790238
Drug: Ubenimex capsule
Normalized name: Ubenimex
DrugBank: Ubenimex (DB03424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ubenimex capsule (30mg daily for 8 weeks)
Study: 14742994
Drug: Daclizumab treatment
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclizumab treatment in combination with tacrolimus and mycophenolate mofetil
Study: 14742994
Drug: Calculated fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calculated fractional excretion of sIL‐2Rα
Study: 11393352
Drug: Conventional cyclic
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional cyclic chemotherapy with rHuG-CSF
Study: 11393352
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy with rHuG-CSF
Study: 9003265
Drug: Low-dose unfractionated
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose unfractionated heparin
Study: 7939756
Drug: Paclitaxel (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (150 mg/m2) followed by Doxorubicin (50 mg/m2)
Study: 7939756
Drug: Paclitaxel (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (200 mg/m2) and Doxorubicin (75 mg/m2) alternating every 3 weeks
Study: 3070520
Drug: DZ 15
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DZ 15 mg
Study: 3070520
Drug: DZ-CR 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: DZ-CR 20 mg
Study: 26668177
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined estrogen plus progestin (0.625 mg conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate)
Study: 23278670
Drug: Mg titanate
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mg titanate
Study: 23278670
Drug: blasted Mg
Normalized name: Arctic Blast
Approvals — FDA: no, EMA: no, PMDA: no
Description: blasted Mg titanate
Study: 23683558
Drug: Intraoperative dobutamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative dobutamine infusion (3 μg/kg per minute or 5 μg/kg per minute)
Study: 20528283
Drug: Classical Sequential
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classical Sequential Advertising (CSA)
Study: 8533005
Drug: Felodipine (Plendil)
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felodipine (Plendil) 5 mg/day
Study: 8533005
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of felodipine with other antihypertensive drugs (ACE inhibitors, beta blockers, diuretics)
Study: 8533005
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of aspirin (75 mg/day)
Study: 339282
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg 15‐methyl‐PGF2alpha‐methyl ester in a rapid releasing base, administered 6 hours prior to operation
Study: 339282
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg 15‐methyl‐PGF2alpha‐methyl ester in a slow releasing base, administered 12 hours prior to operation
Study: 19948506
Drug: Vernakalant (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vernakalant (3 mg/kg infusion for 10 minutes, followed by 2 mg/kg if needed)
Study: 11583479
Drug: Etoricoxib 5
Normalized name: étoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 5 mg
Study: 11583479
Drug: Etoricoxib 10
Normalized name: étoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 10 mg
Study: 11583479
Drug: Etoricoxib 20
Normalized name: étoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 20 mg
Study: 11583479
Drug: Etoricoxib 40
Normalized name: étoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 40 mg
Study: 11583479
Drug: Etoricoxib (5-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib (5-120 mg range)
Study: 9836104
Drug: IgA anti‐transglutaminase
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgA anti‐transglutaminase antibodies by enzyme‐linked immunosorbent assay test
Study: 8015820
Drug: BV (Immunomodulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: BV (Immunomodulation therapy)
Study: 26474041
Drug: Acetaminophen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (500 mg twice daily)
Study: 24471868
Drug: Alfuzosin 10
Normalized name: Alfuzosin 10mg Oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin 10 mg alone (Group A)
Study: 24471868
Drug: Alfuzosin 10
Normalized name: Alfuzosin 10mg Oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin 10 mg plus Propiverine 10 mg (Group B)
Study: 24471868
Drug: Alfuzosin 10
Normalized name: Alfuzosin 10mg Oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin 10 mg plus Propiverine 20 mg (Group C)
Study: 19455984
Drug: Intravenous infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusions of 400 ml of ozonized sodium chloride solution (pO3) containing 1.6 microg/ml of O3 twice weekly for 21 days
Study: 19455984
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (antibacterial therapy only)
Study: 19455984
Drug: Blood ozonization
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood ozonization in combination with antibiotics
Study: 15938923
Drug: CPT‐11 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT‐11 90 ‐ 25 mg/m(2) continuous infusion for 10 h and folinic acid (FA) 30 mg x m(‐2) x d(‐1) + 5‐FU 425 mg x m(‐2) x d(‐1) x 2 d continuous infusion for 48 h, every two weeks for a total of no less than six cycles (Group A)
Study: 15938923
Drug: CPT‐11 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT‐11 90 ‐ 125 mg/m(2) continuous infusion for 10 h every two weeks for a total of no less than six cycles and capecitabine 1250 mg x m(‐2) x d(‐1) by oral divided into two doses, continuously taken without interruption for three months (Group B)
Study: 9137123
Drug: Clomipramine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (200 mg i.v.)
Study: 31436231
Drug: Ultrasound-guided percutaneous
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided percutaneous RFA plus intravenous infusion of LTLD (combination group, n = 11)
Study: 23082846
Drug: ProDisc-L total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProDisc-L total disc replacement (TDR)
Study: 19943947
Drug: Nicotine 4
Normalized name: nicotine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine 4 mg gum or nicotine 10 mg inhaler
Study: 15250817
Drug: Empirically Supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirically Supported Therapies (ESTs)
Study: 11675905
Drug: Co-amoxiclav (625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-amoxiclav (625 mg tablets three times daily for 7 days)
Study: 9041571
Drug: Propofol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (3 mg.kg‐1)/propofol bolus (0.5 mg.kg‐1 every 3 min)
Study: 7705855
Drug: Subcutaneous interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous interferon alpha-2a plus podophyllin 25% W/V administered twice per week, preceded by IFN alpha-2a three times weekly for one week
Study: 7705855
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus podophyllin 25% W/V administered in the same schedule
Study: 3311619
Drug: Estrostep (new
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrostep (new graduated estrogen formulation)
Study: 3311619
Drug: Loestrin 1/20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loestrin 1/20, Loestrin 1.5/30, Norlestrin 1/50 (constant-dosed oral contraceptives)
Study: 3311619
Drug: All four
Normalized name: Jackson's The Original All Fours
Approvals — FDA: no, EMA: no, PMDA: no
Description: All four combination oral contraceptives
Study: 15927989
Drug: Rho-kinase inhibitor
Normalized name: VEGFR 2 Kinase inhibitor I
DrugBank: VEGFR 2 Kinase inhibitor I (DB17061)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rho-kinase inhibitor fasudil
Study: 10407221
Drug: Anabolic-androgenic steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anabolic-androgenic steroids (AAS) for a mean period of 6.5 weeks
Study: 10407221
Drug: Triptorelin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin administration for 5 weeks
Study: 2147527
Drug: 60 mg/day
Normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/day toremifene
Study: 2147527
Drug: 240 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg/day toremifene
Study: 2147527
Drug: 40 mg/day
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day tamoxifen
Study: 6998794
Drug: Trithiozine (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trithiozine (1200 mg/day)
Study: 30983457
Drug: Topical ethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ethyl chloride anesthetic spray
Study: 30983457
Drug: 1% lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine subdermal injection
Study: 31823822
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with methotrexate (MTX) and zoledronic acid (ZOL)
Study: 31823822
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (ZOL) monotherapy
Study: 20193338
Drug: Thalidomide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (50 mg p.o. bid) administered on days 1 to 5 after the start of chemotherapy
Study: 20193338
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (ramosetron 0.3 mg i.v. and metoclopramide 20 mg i.m. 30 min prior to chemotherapy)
Study: 15083445
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (n=12)
Study: 11535548
Drug: 600 mg/day
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/day raloxifene
Study: 9500490
Drug: Fluconazole 150
Normalized name: fluconazole 150 MG
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole 150 mg administered 2 hours before oral contraceptive on pill day 6
Study: 20456248
Drug: 50 U/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 U/ml NT 201 dilution
Study: 20456248
Drug: 20 U/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 U/ml NT 201 dilution
Study: 10227008
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg 17 beta‐oestradiol + 2.5, 5, 10 or 15 mg dydrogesterone (orally once a day)
Study: 8916980
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist plus add-back hormone replacement therapy (HRT)
Study: 8916980
Drug: 25 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 micrograms oestradiol patches plus continuous medroxyprogesterone acetate (5 mg)
Study: 8916980
Drug: Full bone-sparing
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full bone-sparing dose of oral oestradiol (2 mg daily)
Study: 30408383
Drug: Depot Medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot Medroxyprogesterone Acetate combined with Gonadotropin-Releasing Hormone (GnRH) analog
Study: 22506940
Drug: Patient-Controlled Analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-Controlled Analgesia (PCA) with 1 mg IV morphine on-demand doses
Study: 22506940
Drug: Patient-Controlled Analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-Controlled Analgesia (PCA) with 1.5 mg IV morphine on-demand doses
Study: 22506940
Drug: Non-PCA treatment
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-PCA treatment (initial dose of 0.1 mg/kg IV morphine followed by physician-managed analgesia)
Study: 8675589
Drug: Parenteral estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral estrogen (im polyestradiol phosphate, 240 mg twice monthly)
Study: 8675589
Drug: Parenteral testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral testosterone (im injections, 250 mg/week)